Canada has filed its Statement of Defence in Eli Lilly’s NAFTA challenge to the ‘promise utility doctrine’ applied by Canadian courts to invalidate its Strattera and Zyprexa patents. The Statement of Defence characterizes Eli Lilly’s claims as, among other things, seeking to transform the NAFTA tribunal into “a supranational court of appeal from reasoned, principled, and procedurally just domestic court decisions.”
The Canadian Intellectual Property Office has announced that the Trade-mark Agent Qualifying Examination will be held on November 25, 2014 with a deadline for applying of September 4, 2014. This is the first examination since the exemption for lawyers was removed.
Yesterday, the U.S. Court of Appeals for the Federal Circuit issued its decision in Abbvie Deutschland Gmbh & Co. v. Janssen Biotech, Inc. relating to patents on directed to antibodies that bind to and neutralize the activity of human interleukin 12. The CAFC found there was sufficient evidence for the jury to find the patents invalid for lack of written description.